To the Editor: In the VALIDATE-SWEDEHEART trial, Erlinge et al. (Sept. 21 issue)1 compared bivalirudin with heparin monotherapy in patients with acute myocardial infarction who were undergoing percutaneous coronary intervention (PCI). Treatment included the use of one of the new P2Y12 inhibitors (ticagrelor, cangrelor, or prasugrel), which was given at least 60 minutes before PCI. Patients who received or were planned to receive glycoprotein IIb/IIIa inhibitors were excluded from enrollment, and the low rates of ischemic events and stent thrombosis are probably attributable to the early administration of the new P2Y12 inhibitors. In the current era, in which immediate reperfusion . . .

中文翻译：

---

比伐卢定与肝素单药治疗心肌梗死的比较

致编辑：在 VALIDATE-SWEDEHEART 试验中，Erlinge 等人。（9 月 21 日）1 在接受经皮冠状动脉介入治疗 (PCI) 的急性心肌梗死患者中比较了比伐卢定与肝素单药治疗。治疗包括使用一种新型 P2Y12 抑制剂（替格瑞洛、坎格雷洛或普拉格雷），在 PCI 前至少 60 分钟给予。接受或计划接受糖蛋白 IIb/IIIa 抑制剂的患者被排除在招募之外，缺血事件和支架血栓形成的低发生率可能归因于新型 P2Y12 抑制剂的早期给药。在当今时代，即刻再灌注。。。